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ABSTRACT
Background: Atrial fibrillation (AF) affects around 2%
of the population and early detection is beneficial,
allowing patients to begin potentially life-saving
anticoagulant therapies. Blood pressure (BP) monitors
may offer an opportunity to screen for AF.
Aim: To identify and appraise studies which report the
diagnostic accuracy of automated BP monitors used
for opportunistic AF detection.
Methods: A systematic search was performed of the
MEDLINE, MEDLINE In-Process and EMBASE literature
databases. Papers were eligible if they described
primary studies of the evaluation of a BP device for AF
detection, were published in a peer-reviewed journal
and reported values for the sensitivity and specificity.
Included studies were appraised using the QUADAS-2
tool to assess their risk of bias and applicability to
opportunistic AF detection. Values for the sensitivity
and specificity of AF detection were extracted from
each paper and compared.
Results and Conclusions: We identified seven
papers evaluating six devices from two manufacturers.
Only one study scored low risk in all of the QUADAS-2
domains. All studies reported specificity >85% and 6
reported sensitivity >90%. The studies showed that BP
devices with embedded algorithms for detecting
arrhythmias show promise as screening tools for AF,
comparing favourably with manual pulse palpation. But
the studies used different methodologies and many
were subject to potential bias. More studies are needed
to more precisely define the sensitivity and specificity
of opportunistic screening for AF during BP
measurement before its clinical utility in the population
of interest can be assessed fully.
INTRODUCTION
Atrial ﬁbrillation (AF) is a common cardiac
arrhythmia that affects around 2% of the
population and around 8% of those aged
over 75 years.1 The presence of AF can
increase a patient’s risk of stroke by up to a
factor of ﬁve;2 however, this risk can be sig-
niﬁcantly reduced through anticoagulation
therapy for those considered at medium or
high risk according to the CHA2DS2-VASc
scoring system,3 making the early detection
of AF beneﬁcial. In the UK, opportunistic
screening for AF has been shown to be
cost-effective.4
Routine measurement of blood pressure
(BP) is one opportunity for detecting AF. In
the UK, the evidence-based National Institute
for Health and Care Excellence (NICE) has
published guidance on the clinical manage-
ment of hypertension.5 This guidance recom-
mends pulse palpation before taking a BP
measurement as some automated sphygmo-
manometers are known to be inaccurate for
patients with an irregular pulse. Some manu-
facturers have turned this problem into an
advantage and have introduced automated
sphygmomanometers that incorporate algo-
rithms for detecting AF. In 2013 NICE pub-
lished a medical technology guidance which
concluded that the use of these devices could
be beneﬁcial in primary care.6 7
In this paper, we aim to identify all
primary studies that have evaluated the use
of automated sphygmomanometers for the
detection of AF against a reference standard,
to appraise these studies based on their rele-
vance to opportunistic AF detection and to
compare their results for the sensitivity and
speciﬁcity of AF detection.
METHODS
A systematic search was performed in August
2014 of the MEDLINE, MEDLINE In-Process
and EMBASE literature databases using the
keywords ‘blood pressure device’ and ‘atrial
ﬁbrillation screening’ and subject headings
‘blood pressure determination’, ‘blood pres-
sure monitoring, ambulatory’, ‘sphygmoman-
ometers’, ‘atrial ﬁbrillation’ and ‘cardiac
arrhythmias’. The search was restricted to
English language, non-animal studies pub-
lished between January 1990 and August
2014. Papers were eligible if they described a
primary evaluation of at least one BP device
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for the detection of AF, were published in a peer-
reviewed journal and reported values for the sensitivity
and speciﬁcity of AF detection in the population
studied. One person (SAK) screened the identiﬁed
titles and abstracts for eligible studies. Studies that ful-
ﬁlled all of the eligibility criteria and those which could
not be ruled out on the basis of title and abstract were
retrieved in full-text form. These were further reviewed
until only studies that fulﬁlled the eligibility criteria
remained.
The study characteristics and reported values for the
sensitivity and speciﬁcity of AF detection, compared with
a reference standard, were extracted from each paper.
We appraised the studies using the QUADAS-2 tool8 for
their risk of bias and applicability to the clinical
problem (ie, detection of AF during opportunistic
screening) against four domains: patient selection,
index test, reference standard and ﬂow and timing. For
each paper, the contingency tables were reconstructed.
To ensure consistency, CIs for sensitivity and speciﬁcity
were estimated using a binomial approximation as
described by Clopper and Pearson.9
RESULTS
Search results
Figure 1 shows the Preferred Reporting Items for
Systematic Review and Meta-Analyses (PRISMA) ﬂow
chart depicting the search results at each stage.10 We
identiﬁed seven papers describing primary studies.11–17
Of these, six were found during the main search; one
further paper was published after the search date and
was identiﬁed by a journal alert using the same search
criteria.17 The studies included six devices from two
manufacturers. Two of the papers analysed more than
one device (table 1).
Appraisal of risk of bias and study applicability
The seven studies were appraised using the QUADAS-2
tool8 (table 2) which considers four different domains
(patient selection, index test, reference standard and
ﬂow and timing). Each of the four domains is appraised
in terms of risk of bias and for the ﬁrst three the applic-
ability of the study to the review question is also consid-
ered. One of the eligible studies scored low risk over all
four domains.16
Patient selection
All of the included studies selected patients based on
predeﬁned criteria and so were considered to be at a
low risk of bias for patient selection.
Three studies were considered to have low applicability
to the review question (detection of AF from opportunis-
tic screening). In two of these, the authors studied parti-
cipants from populations likely to beneﬁt from
opportunistic screening,11 15 but who also had additional
risk factors for AF, which may limit the extent to which
their ﬁndings can be applied to opportunistic screening.
In the remaining study, an experimental case-control
Figure 1 PRISMA diagram
showing the results from each
stage of the search process.
PRISMA, Preferred Reporting
Items for Systematic Review and
Meta-Analyses.
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design was adopted12 rather than enrolling a consecutive
or random sample of patients, reducing the applicability
to opportunistic screening. For the majority of the
studies the objective was to assess the performance of
the device in the chosen population, however two were
application studies; one considering self-monitoring at
home15 and the other in general practice.16
Of the studies considered highly applicable to oppor-
tunistic screening, Kearley et al16 considered a popula-
tion most likely to beneﬁt—primary care patients over
75 years—and recruited a large number (n=999) of par-
ticipants to estimate test sensitivity with a precision
better than 10%. Other authors13 14 17 considered popu-
lations also likely to beneﬁt from opportunistic screen-
ing but with a higher prevalence of AF, such as
cardiology or hypertension clinic outpatients.
Index test
Three of the included studies were considered at high
risk of bias.11–13 In these studies the authors calculated
the sensitivity and speciﬁcity of AF detection using all
measurements from all patients, with the assumption
that each measurement was independent. However
repeated measurements within individuals are likely to
be correlated, potentially breaking the assumption of
independence and leading to underestimates of meas-
urement uncertainty.
Three of the seven included studies used a valid index
test (automated BP monitor with embedded AF detec-
tion algorithm) and so were considered to have high
applicability to the review question.13 15 16 Three of the
seven studies used devices which claim to detect irregu-
lar heartbeat or arrhythmias but make no claims about
Table 1 Summary of study characteristics for each of the included studies
Population
Paper Device studied
Reference
standard
Number of
measurements
per participant
Number of
participants
Male
(%)
Mean age
(years)
AF
prevalence
(%)
Wiesel et al11 Omron 712C 12-lead ECG 2 450 59 69 12.0
Stergiou et al12 Microlife
BPA100 Plus
12-lead ECG
+1-lead ECG
3 73 66 71 37.0
Wiesel et al13 Microlife BPM
BP3MQ1–2D
12-lead ECG 3 405 51 73 23.0
Marazzi et al (a)14 Microlife BP
A200 Plus
12-lead ECG 1 503 54 67 20.1
Marazzi et al (b)14 Omron M6 12-lead ECG 1 503 54 67 20.1
Wiesel et al15 Microlife BPM
BP3MQ1–2D
ECG event
monitor
1–4 per day 139 37 67 12.9
Kearley et al16 WatchBP 12-lead ECG 1 999 49 80 7.9
Wiesel et al (a)17 Microlife BP
A200 Plus
12-lead ECG 3 183 59 74 16.4
Wiesel et al17 (b) Omron M6 12-lead ECG 1 183 59 74 16.4
AF, atrial fibrillation.
Table 2 Summary of the results from the QUADAS-2 tool for each of the included papers
Risk of bias Applicability concerns
Study
Patient
selection
Index
test
Reference
standard
Flow and
timing
Patient
selection
Index
test
Reference
standard
Wiesel et al11
Stergiou et al12
Wiesel et al13
Marazzi et al14
Wiesel et al15
Kearley et al16
Wiesel et al17
, low risk; , high risk; , unclear risk.
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AF detection in particular (Omron M6 and Microlife BP
A100 plus).12 14 17 The remaining study used a modiﬁed
device and the collected data were downloaded onto a
laptop for analysis.11
Throughout all of the included studies, there was a
large degree of variation in the methods used for inter-
preting the index test. Two of the papers14 16 made a
diagnosis of AF on the basis of a single BP measure-
ment. The remainder of the studies took multiple mea-
surements from each participant and assessed the
impact of different interpretations on the sensitivity and
speciﬁcity. Four of the studies considered individual
measurements and majority rule methods.11–13 17 The
remaining study,15 carried out in the home environment
over 30 days with between one and four measurements
per day, considered two methods: using the ﬁrst reading
of the day only and using an overall daily AF status
based on the repeat measurements.
Reference standard
The reference standard for AF diagnosis is a 12-lead
ECG interpreted by a certiﬁed cardiologist.18 Of the
seven papers examined, four performed a 12-lead ECG
prior to or shortly after the BP measurement that was
interpreted by at least one cardiologist blinded to the
result of the index test.13 14 16 17 These studies were
considered to have a low risk of bias and high
applicability to the review question (likely to correctly
classify AF).
The three remaining studies were either unclear
about their use of a reference standard or adopted dif-
ferent approaches. Stergiou et al12 made the diagnosis of
AF on the basis of a 12-lead ECG recording interpreted
by a cardiologist; however, no blinding was mentioned
(questionable risk of bias). Wiesel et al11 did not state
the number of leads used for the ECG nor how the ECG
was interpreted, so the risk of bias and applicability were
classiﬁed as questionable. The remaining study,15 which
was the only one to assess a device in the home environ-
ment, used an ECG event monitor that was used by the
participant to obtain a 60 s recording prior to each BP
reading. This method is less likely to correctly diagnose
AF (low applicability); however, the results were inter-
preted by a blinded cardiologist (low risk of bias).
Flow and timing
Two main sources of bias regarding the ﬂow and timing
within the included studies were considered: the time
interval between the reference standard and the index
test and inappropriate inclusions/exclusions of partici-
pants following enrolment. Studies were considered to
have a high risk of bias (table 2) if they did not fulﬁl the
criteria for either category.
As AF can be paroxysmal, the ECG and BP measure-
ments should be performed simultaneously to ensure the
validity of the reference test. However, given the practical
considerations, for this appraisal, the time interval was
considered adequate if the ECG and BP measurements
were performed within the same clinic visit. Marazzi
et al14 was the only study to record 12-lead ECG and BP
measurements simultaneously. Stergiou et al12 performed
a baseline 12-lead ECG prior to the measurement and
then single-lead ECG during the BP measurement. The
remainder of the studies performed the reference test
during the same clinic visit (and all within 30 min of the
BP measurements) and so all included studies were con-
sidered at low risk of bias for this category.
Three studies were considered to have high or ques-
tionable risk of bias for inappropriate inclusions/exclu-
sions of participants (table 2). Marazzi et al14 excluded
enrolled patients who had >5 mm Hg difference in BP
when measured in both arms. In this case, the measure-
ment uncertainties may be greater than reported as par-
ticipants in which measurement was difﬁcult have been
excluded. Wiesel et al11 included patients returning for
repeat tests in the analysis multiple times without taking
into account repeated-measures effects. Both of these
papers were therefore classed as having an increased
risk of bias. The paper by Stergiou et al12 was considered
to have a questionable risk of bias as the authors state in
the text that two participants only had two BP measure-
ments made instead of three; however, this is not in
agreement with the results provided in the correspond-
ing table in the paper where 72 of 73 participants are
accounted for. In the 2013 paper by Wiesel et al,15
several participants did not adhere to the guidelines and
so could not be included in the analysis; however, this
was beyond the control of the authors and suitable cor-
rections were made when reporting the results, so this
study was considered to have a low risk of bias.
Review of study findings
The extracted results for the sensitivity and speciﬁcity
are shown in ﬁgure 2. For the studies where multiple
methods for assessing the index test were investigated,
the best reported values are shown. In one study14 a dis-
crepancy relating to the speciﬁcity of the Microlife BP
A200 was noted between the result quoted in the text
and the value calculated from the results table; we used
the latter. The studies consistently showed that AF detec-
tion speciﬁcities >85% can be achieved irrespective of
the device used, provided that there is an appropriate
method for interpreting the index test. Six of the seven
studies reported sensitivity >90%. However, in the
remaining paper,17 one device demonstrated a much
lower sensitivity (30%, Omron M6). This result was in
direct conﬂict with the results obtained by Marazzi
et al14 who found a sensitivity of 100% for the same
device while still achieving high speciﬁcity. Wiesel et al
speculate that this difference may be due to the popula-
tion used by Marazzi et al, which had a high prevalence
of AF and relatively young age. However, there have
been other studies using populations of similar age11
and a higher prevalence of AF12 13 that showed high sen-
sitivities and speciﬁcities, so the discrepancy remains
unexplained.
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DISCUSSION
Summary
Seven papers were found that reported primary studies
of AF detection using automated BP devices. The papers
tested several methods for interpreting the index test
results in a variety of patient populations and only one
of the papers scored low risk in all four of the
QUADAS-2 domains.16 In general, the results were con-
clusive, with all speciﬁcities reported to exceed 85% and
most detection sensitivities reported to exceed 90%
(one study reported a device sensitivity of 30%).
Strengths and limitations
This review employed wide search criteria to capture all
of the relevant articles following which strict inclusion
criteria were applied to identify articles determining the
diagnostic accuracy of these devices in particular popula-
tions and settings. However, we appreciate that the focus
of other studies may have been clinical utility rather
than diagnostic accuracy. For example, Ermini et al19
studied a large population to investigate the effect of
using a modiﬁed BP device on the number of new cases
of AF detected, and Wiesel et al20 assessed the rate
of false positives in a group of 19 participants using
the device in a home environment. Additionally,
non-peer-reviewed work has been excluded such as the
research letter by Huang et al,21 a small scale study asses-
sing the use of these devices in the detection of cardiac
arrhythmias, not speciﬁcally AF.
Comparison with existing literature
A previous review of this topic by Verberk and de
Leeuw22 focused on how the interpretation of the index
test affected diagnostic accuracy. They pooled data to
determine mean values for sensitivity and speciﬁcity,
assuming homogeneity of the studies. However, we
found that previous studies had heterogeneous popula-
tions and index tests. This is particularly highlighted
through the studies by Marazzi et al14 and Wiesel et al,17
where two different studies of the same device gave sub-
stantially different results. Additionally, our paper high-
lights the three peer-reviewed studies15–17 published
since the Verberk and de Leeuw paper, emphasising
that this is an active area of research.
A recently published meta-analysis by Taggar et al23
identiﬁes published methods for detecting AF and
includes automated BP devices as well as pulse palpa-
tion, smartphone applications and non-12-lead ECG
devices. Of the techniques identiﬁed, they found BP
monitors and non-12-lead ECG devices to have the
highest diagnostic accuracy. Their review compared dif-
ferent technologies for AF detection in a range of
patients and settings, whereas ours speciﬁcally considers
diagnostic accuracy studies for opportunistic detection
of AF during BP measurement.
A further review and meta-analysis by Verberk et al24
described evidence and practice recommendations relat-
ing to AF detection using blood pressure devices. Their
paper focused on a particular family of BP devices
which incorporate a speciﬁc AF detection algorithm
(Microlife AG, Switzerland) and concluded that three
sequential measurements should be used, and that a sus-
pected diagnosis be conﬁrmed by ECG. They also pro-
posed that automated at-home or ambulatory BP
measurements may increase the chance of diagnosis of
patients with paroxysmal or asymptomatic AF. The
present review was not restricted to a particular family of
devices.
Implications for research and practice
Eligible studies reported to date show good agreement
and high values for both sensitivity and speciﬁcity.
However, the presence of an outlier raises some con-
cerns about the applicability of the studies to routine
practice. There is also a lack of homogeneity between
the study designs. Many have been carried out in small
Figure 2 Sensitivity and
specificity of AF detection for
each of the included studies. CIs
have been calculated using a
binomial approximation as
described by Clopper and
Pearson.9
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patient groups which are not representative of the popu-
lation of interest or use BP devices which do not claim
to be suitable for AF detection. We found only one study
of high methodological quality which speciﬁcally consid-
ered the population most likely to beneﬁt from oppor-
tunistic screening,16 highlighting the need for further
large-scale, well-designed studies. The recently published
study protocol by Uittenbogaart et al25 describes a year-
long randomised control trial that aims to test the use of
automated BP devices for opportunistic AF detection
(alongside other screening methods) in 96 primary care
practices in the Netherlands and will provide further evi-
dence in this area.
BP devices with embedded algorithms show promise
as a screening tool for AF. The high sensitivities and spe-
ciﬁcities reported for these devices compare favourably
with the current screening practice of manual pulse pal-
pation which has the sensitivity and speciﬁcity of 94%
and 72%, respectively.26 The introduction of these
devices into routine practice could provide a simple,
objective method for AF screening in high-risk groups.
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